CN112351994A - 一种多受体激动剂及其医药用途 - Google Patents

一种多受体激动剂及其医药用途 Download PDF

Info

Publication number
CN112351994A
CN112351994A CN202080002789.8A CN202080002789A CN112351994A CN 112351994 A CN112351994 A CN 112351994A CN 202080002789 A CN202080002789 A CN 202080002789A CN 112351994 A CN112351994 A CN 112351994A
Authority
CN
China
Prior art keywords
amino acid
acid residue
lys
glu
residue selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080002789.8A
Other languages
English (en)
Other versions
CN112351994B (zh
Inventor
吴方舟
王雷
刘潇
吴然
花海清
包如迪
王小雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN112351994A publication Critical patent/CN112351994A/zh
Application granted granted Critical
Publication of CN112351994B publication Critical patent/CN112351994B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一系列多肽双重激动剂化合物及其可药用盐的药物组合物，其对人类胰高血糖素样肽‑1(GLP‑1)受体和人类血糖依赖性促胰岛素多肽(GlP)受体具有双重激动剂作用，可以用于非胰岛素依赖性糖尿病、胰岛素依赖性糖尿病和肥胖症等相关疾病的治疗。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN202080002789.8A 2019-04-11 2020-04-10 一种多受体激动剂及其医药用途 Active CN112351994B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910290162 2019-04-11
CN2019102901626 2019-04-11
CN2019111209066 2019-11-15
CN201911120906 2019-11-15
PCT/CN2020/084247 WO2020207477A1 (zh) 2019-04-11 2020-04-10 Glp-1和gip受体双重激动剂化合物及其应用

Publications (2)

Publication Number Publication Date
CN112351994A true CN112351994A (zh) 2021-02-09
CN112351994B CN112351994B (zh) 2024-06-07

Family

ID=72752204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080002789.8A Active CN112351994B (zh) 2019-04-11 2020-04-10 一种多受体激动剂及其医药用途

Country Status (11)

Country Link
US (1) US20220168396A1 (zh)
EP (1) EP3954701A4 (zh)
JP (1) JP7577678B2 (zh)
KR (1) KR20210149747A (zh)
CN (1) CN112351994B (zh)
AU (1) AU2020256648B2 (zh)
BR (1) BR112021020071A2 (zh)
CA (1) CA3136163A1 (zh)
MX (1) MX2021012277A (zh)
TW (1) TW202104253A (zh)
WO (1) WO2020207477A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115521368A (zh) * 2021-06-25 2022-12-27 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
CN116023444A (zh) * 2022-08-12 2023-04-28 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
WO2025242218A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 一种多肽激动剂，其制备方法及医药用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
WO2021239082A1 (zh) * 2020-05-29 2021-12-02 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
MX2023000303A (es) * 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
CN114617956B (zh) * 2020-12-10 2023-10-03 江苏中新医药有限公司 一种高效降糖的蛋白质药物
CN115124602B (zh) * 2021-03-25 2024-01-26 博瑞生物医药（苏州）股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
US12215133B2 (en) * 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
MX2023014771A (es) * 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CA3237796A1 (en) * 2021-11-12 2023-05-19 Zhenbin Li Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
MX2024006492A (es) * 2021-12-01 2024-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de doble agonista de los receptores glp-1 y gip y uso de la misma.
MX2024007861A (es) * 2022-01-10 2024-07-09 Jiangsu Hansoh Pharmaceutical Group Co Ltd Composicion farmaceutica estable de agonista de receptor, metodo de preparacion y su aplicacion.
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868A (zh) * 2009-07-30 2011-03-23 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN104470948A (zh) * 2012-05-03 2015-03-25 西兰制药公司 Gip-glp-1双激动剂化合物及方法
CN104902920A (zh) * 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2440235A1 (en) * 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
EP2694095B1 (en) * 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CN103861089B (zh) * 2012-12-17 2019-06-28 江苏豪森药业集团有限公司 Glp-1类似物的衍生物或其可药用盐注射液及其制备方法和用途
WO2015095684A1 (en) * 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868A (zh) * 2009-07-30 2011-03-23 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN104470948A (zh) * 2012-05-03 2015-03-25 西兰制药公司 Gip-glp-1双激动剂化合物及方法
CN104902920A (zh) * 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAU， J.等: "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115521368A (zh) * 2021-06-25 2022-12-27 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
CN116023444A (zh) * 2022-08-12 2023-04-28 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
WO2025242218A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 一种多肽激动剂，其制备方法及医药用途

Also Published As

Publication number Publication date
KR20210149747A (ko) 2021-12-09
AU2020256648B2 (en) 2026-01-15
CN112351994B (zh) 2024-06-07
EP3954701A4 (en) 2023-09-06
EP3954701A1 (en) 2022-02-16
MX2021012277A (es) 2021-11-12
JP7577678B2 (ja) 2024-11-05
WO2020207477A9 (zh) 2020-11-26
JP2022527803A (ja) 2022-06-06
WO2020207477A1 (zh) 2020-10-15
US20220168396A1 (en) 2022-06-02
AU2020256648A1 (en) 2021-11-04
BR112021020071A2 (pt) 2021-12-14
CA3136163A1 (en) 2020-10-15
TW202104253A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
CN112351994B (zh) 一种多受体激动剂及其医药用途
CN114222755B (zh) Glp-1和gip受体双重激动剂化合物及其应用
CN113383014B (zh) 双受体重激动剂化合物及其药物组合物
CN111825758B (zh) Glp-1和gip共激动剂化合物
EP2185178B1 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN118103391A (zh) Glp-1受体和gip受体双重激动剂的药物组合物及其用途
RU2816492C2 (ru) Мультирецепторный агонист и его медицинское применение
HK40043112A (zh) 一种多受体激动剂及其医药用途
HK40051504A (zh) 双受体重激动剂化合物及其药物组合物
RU2848325C1 (ru) Соединение с двойной агонистической активностью в отношении рецепторов glp-1 и gip и его применение
HK40069563A (zh) Glp-1和gip受体双重激动剂化合物及其应用
HK40043112B (zh) 一种多受体激动剂及其医药用途
AU2026202757A1 (en) Multi-receptor agonist and medical use thereof
CN115521368B (zh) 毒蜥外泌肽-4衍生物
HK40069563B (zh) Glp-1和gip受体双重激动剂化合物及其应用
HK40051504B (zh) 双受体重激动剂化合物及其药物组合物
AU2024291989A1 (en) Glp-1, gip and gcg receptor triagonist and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40043112

Country of ref document: HK

GR01 Patent grant